Stay updated on CK-2127107 in ALS: FORTITUDE-ALS Clinical Trial
Sign up to get notified when there's something new on the CK-2127107 in ALS: FORTITUDE-ALS Clinical Trial page.

Latest updates to the CK-2127107 in ALS: FORTITUDE-ALS Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed a reference to an erratum related to a phase III trial of tirasemtiv for amyotrophic lateral sclerosis.SummaryDifference0.3%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed study information regarding CK-2127107 (reldesemtiv) for ALS, while adding new references to collaborators and a revision update.SummaryDifference21%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.2%
- Check45 days agoChange DetectedDifference0.1%
Stay in the know with updates to CK-2127107 in ALS: FORTITUDE-ALS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CK-2127107 in ALS: FORTITUDE-ALS Clinical Trial page.